Menno Tamminga1, Kiki C Andree2, Hilda van den Bos3, T Jeroen N Hiltermann1, Anouk Mentink2, Diana C J Spierings3, Peter Lansdorp3,4,5, Wim Timens6, Ed Schuuring6, Leon W M M Terstappen2, Harry J M Groen7. 1. Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 2. Department of Medical Cell BioPhysics, Faculty of Sciences and Technology, University of Twente, Enschede, The Netherlands. 3. European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 4. Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, V5Z 1L3, Canada. 5. Department of Medical Genetics, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada. 6. Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 7. Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. m.tamminga@umcg.nl.
Abstract
BACKGROUND: Circulating tumour cells (CTCs) can be used to monitor cancer longitudinally, but their use in non-small cell lung cancer (NSCLC) is limited due to low numbers in the peripheral blood. Through diagnostic leukapheresis (DLA) CTCs can be obtained from larger blood volumes. METHODS: Patients with all stages of NSCLC were selected. One total body blood volume was screened by DLA before and after treatment. Peripheral blood was drawn pre- and post DLA for CTC enumeration by CellSearch. CTCs were detected in the DLA product (volume equalling 2 × 108 leucocytes) and after leucocyte depletion (RosetteSep, 9 mL DLA product). Single-cell, whole-genome sequencing was performed on isolated CTCs. RESULTS: Fifty-six patients were included. Before treatment, CTCs were more often detected in DLA (32/55, 58%) than in the peripheral blood (pre-DLA: 18/55, 33%; post DLA: 13/55, 23%, both at p < 0.01). CTCs per 7.5 mL DLA product were median 9.2 times (interquartile range = 5.6-24.0) higher than CTCs in 7.5 mL blood. RosetteSEP did not significantly improve CTC detection (pretreatment: 34/55, 62%, post treatment: 16/34, 47%) and CTCs per mL even decreased compared to DLA (p = 0.04).. Patients with advanced-stage disease with DLA-CTC after treatment showed fewer tumour responses and shorter progression-free survival (PFS) than those without DLA-CTC (median PFS, 2.0 vs 12.0 months, p < 0.01). DLA-CTC persistence after treatment was independent of clinical factors associated with shorter PFS (hazard ratio (HR) = 5.8, 95% confidence interval (CI), 1.4-35.5, p = 0.02). All evaluable CTCs showed aneuploidy. CONCLUSIONS: DLA detected nine times more CTCs than in the peripheral blood. The sustained presence of CTCs in DLA after treatment was associated with therapy failure and shortened PFS. TRIAL REGISTRATION: The study was approved by the Medical Ethical Committee (NL55754.042.15) and was registered in the Dutch trial register (NL5423).
BACKGROUND: Circulating tumour cells (CTCs) can be used to monitor cancer longitudinally, but their use in non-small cell lung cancer (NSCLC) is limited due to low numbers in the peripheral blood. Through diagnostic leukapheresis (DLA) CTCs can be obtained from larger blood volumes. METHODS: Patients with all stages of NSCLC were selected. One total body blood volume was screened by DLA before and after treatment. Peripheral blood was drawn pre- and post DLA for CTC enumeration by CellSearch. CTCs were detected in the DLA product (volume equalling 2 × 108 leucocytes) and after leucocyte depletion (RosetteSep, 9 mL DLA product). Single-cell, whole-genome sequencing was performed on isolated CTCs. RESULTS: Fifty-six patients were included. Before treatment, CTCs were more often detected in DLA (32/55, 58%) than in the peripheral blood (pre-DLA: 18/55, 33%; post DLA: 13/55, 23%, both at p < 0.01). CTCs per 7.5 mL DLA product were median 9.2 times (interquartile range = 5.6-24.0) higher than CTCs in 7.5 mL blood. RosetteSEP did not significantly improve CTC detection (pretreatment: 34/55, 62%, post treatment: 16/34, 47%) and CTCs per mL even decreased compared to DLA (p = 0.04).. Patients with advanced-stage disease with DLA-CTC after treatment showed fewer tumour responses and shorter progression-free survival (PFS) than those without DLA-CTC (median PFS, 2.0 vs 12.0 months, p < 0.01). DLA-CTC persistence after treatment was independent of clinical factors associated with shorter PFS (hazard ratio (HR) = 5.8, 95% confidence interval (CI), 1.4-35.5, p = 0.02). All evaluable CTCs showed aneuploidy. CONCLUSIONS: DLA detected nine times more CTCs than in the peripheral blood. The sustained presence of CTCs in DLA after treatment was associated with therapy failure and shortened PFS. TRIAL REGISTRATION: The study was approved by the Medical Ethical Committee (NL55754.042.15) and was registered in the Dutch trial register (NL5423).
Authors: Véronique Hofman; Christelle Bonnetaud; Marius I Ilie; Philippe Vielh; Jean Michel Vignaud; Jean François Fléjou; Sylvie Lantuejoul; Eric Piaton; Nadine Mourad; Catherine Butori; Eric Selva; Michel Poudenx; Stéphanie Sibon; Sabrina Kelhef; Nicolas Vénissac; Jean-Philippe Jais; Jérôme Mouroux; Thierry Jo Molina; Paul Hofman Journal: Clin Cancer Res Date: 2010-11-23 Impact factor: 12.531
Authors: Elizabeth A Punnoose; Siminder Atwal; Weiqun Liu; Rajiv Raja; Bernard M Fine; Brett G M Hughes; Rodney J Hicks; Garret M Hampton; Lukas C Amler; Andrea Pirzkall; Mark R Lackner Journal: Clin Cancer Res Date: 2012-04-05 Impact factor: 12.531
Authors: Matthew G Krebs; Jian-Mei Hou; Robert Sloane; Lee Lancashire; Lynsey Priest; Daisuke Nonaka; Tim H Ward; Alison Backen; Glen Clack; Andrew Hughes; Malcolm Ranson; Fiona H Blackhall; Caroline Dive Journal: J Thorac Oncol Date: 2012-02 Impact factor: 15.609
Authors: Johannes C Fischer; Dieter Niederacher; Stefan A Topp; Ellen Honisch; Sarah Schumacher; Norma Schmitz; Luisa Zacarias Föhrding; Christian Vay; Imke Hoffmann; Nikola S Kasprowicz; Philip G Hepp; Svjetlana Mohrmann; Ulrike Nitz; Antje Stresemann; Thomas Krahn; Tanja Henze; Evelyn Griebsch; Katharina Raba; Jutta M Rox; Folker Wenzel; Christoph Sproll; Wolfgang Janni; Tanja Fehm; Christoph A Klein; Wolfram Trudo Knoefel; Nikolas H Stoecklein Journal: Proc Natl Acad Sci U S A Date: 2013-09-24 Impact factor: 11.205
Authors: Menno Tamminga; Sanne de Wit; Ed Schuuring; Wim Timens; Leon W M M Terstappen; T Jeroen N Hiltermann; Harry J M Groen Journal: Transl Lung Cancer Res Date: 2019-12
Authors: Sanne de Wit; Guus van Dalum; Aufried T M Lenferink; Arjan G J Tibbe; T Jeroen N Hiltermann; Harry J M Groen; Cees J M van Rijn; Leon W M M Terstappen Journal: Sci Rep Date: 2015-07-17 Impact factor: 4.379
Authors: Kiki C Andree; Anouk Mentink; Leonie L Zeune; Leon W M M Terstappen; Nikolas H Stoecklein; Rui P Neves; Christiane Driemel; Rita Lampignano; Liwen Yang; Hans Neubauer; Tanja Fehm; Johannes C Fischer; Elisabetta Rossi; Mariangela Manicone; Umberto Basso; Piero Marson; Rita Zamarchi; Yohann Loriot; Valerie Lapierre; Vincent Faugeroux; Marianne Oulhen; Françoise Farace; Gemma Fowler; Mariane Sousa Fontes; Berni Ebbs; Maryou Lambros; Mateus Crespo; Penny Flohr; Johann S de Bono Journal: Int J Cancer Date: 2018-09-19 Impact factor: 7.396